Vaxart Announces $40 Million Underwritten Offering of Common Stock
June 13, 2024 19:07 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering...
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
June 13, 2024 16:15 ET
|
Vaxart, Inc.
— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early...
Seasonal Influenza Vaccines Market Forecast to Hit $17.77 Billion by 2033: The Brainy Insights
June 13, 2024 09:00 ET
|
The Brainy Insights
Newark, June 13, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the global seasonal influenza vaccines market will grow from USD 7.82 Billion in 2023 to USD 17.77 Billion by 2033....
Global Breast Biopsy Devices Market Size To Exceed USD 2.9 Billion By 2033 | CAGR Of 5.49%
June 13, 2024 01:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States, June 13, 2024 (GLOBE NEWSWIRE) -- The Global Breast Biopsy Devices Market Size is Anticipated to Exceed USD 2.9 Billion by 2033, Growing at a CAGR of 5.49% from 2023 to...
“The Only Presale You Need in 2024” BlockDAG Network Grows at a Speed of $500,000 a Day, A Step-to-Step on How You Can Join In
June 12, 2024 12:00 ET
|
BlockDAG Network
London, UK, June 12, 2024 (GLOBE NEWSWIRE) -- In the dynamic and ever-evolving world of cryptocurrency, identifying the next big opportunity can feel like finding a needle in a haystack....
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
June 12, 2024 08:00 ET
|
Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
June 12, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ...
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
June 12, 2024 01:30 ET
|
CROSSJECT
Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports...
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
June 11, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the conference on June 19, 2024.
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...